Argus•January 20, 2021

MYGN: Raising target price to $22.00

Symbols

Sector(s)

Healthcare

Rating

Current Price

$17.98

Price Target

Earnings Estimate

Summary

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an indiv

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level